Author

Avina A. Singh

Institution: Minnesota Oncology

Observed institution: Minnesota Oncology

OpenAlex ID: A5018971176

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

2020 · Shaji Kumar, Susanna J. Jacobus, et al. · Journal of Clinical Oncology · 31

Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ENDURANCE phase 3 trial.

2025 · Shaji Kumar, Edward A. Faber, et al. · Journal of Clinical Oncology · 2

Toward understanding toxicity over time (ToxT) in myeloma cooperative group trials: Feasibility of a novel longitudinal adverse event analysis in ECOG-ACRIN E1A06.

2018 · Susanna J. Jacobus, Paul J. Novotny, et al. · Journal of Clinical Oncology

Works count: 3

Citation count: 33

H-index: 2

I10-index: 1